Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: Mechanistic involvement of AKT catalytic activation loop cysteines

Molecular Cancer Therapeutics

Volumn 6, Issue 11, 2007, Pages 3028-3038

  Toral Barza, Lourdes ^a   Zhang, Wei Guo ^a   Huang, Xinyi ^a   McDonald, Leonard A ^a   Salaski, Edward J ^a   Barbieri, Laurel R ^a   Ding, Wei Dong ^a   Krishnamurthy, Girija ^a   Yong, Bo Hu ^a   Lucas, Judy ^a   Bernan, Valerie S ^a   Cai, Ping ^a   Levin, Jeremy I ^a   Mansour, Tarek S ^a   Gibbons, James J ^a   Abraham, Robert T ^a   Yu, Ker ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE DERIVATIVE; FRENOLICIN B; GROWTH FACTOR; LACTOQUINOMYCIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; QUINONE DERIVATIVE; STAUROSPORINE; TARGET OF RAPAMYCIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOCHEMISTRY; CATALYSIS; CONTROLLED STUDY; EMBRYO; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; RAT; TRANSLATION INITIATION;

ADENOSINE TRIPHOSPHATE; ALLOSTERIC REGULATION; ANIMALS; CATALYSIS; CELL LINE, TUMOR; CYSTEINE; DOWN-REGULATION; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; KINETICS; NAPHTHOQUINONES; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RNA CAPS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TIME FACTORS;

EID: 36749047453     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0211     Document Type: Article

References (41)

1. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257-62.
2. Coffer PJ, Woodgett JR. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem 1991;201:475-81.
3. Bellacosa A, Testa JR, Staal SP, Tsichlis PN. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 1991;254:274-7.
4. Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B byinsulin and IGF-1. EMBO J 1996;15:6541-51.
5. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 1999;96:4240-5.
6. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
7. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005;24:7455-64.
8. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.
9. Mazure NM, Chen EY, Laderoute KR, Giaccia AJ. Induction of vascular endothelial growth factor byhy poxia is modulated bya phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 1997;90:3322-31.
10. Zundel W, Schindler C, Haas-Kogan D, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000;14:391-6.
11. Davies MA, Lu Y, Sano T, et al. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res 1998;58:5285-90.
12. Jetzt A, Howe JA, Horn MT, et al. Adenoviral-mediated expression of a kinase-dead mutant of Akt induces apoptosis selectively in tumor cells and suppresses tumor growth in mice. Cancer Res 2003;63:6697-706.
13. Liu X, Shi Y, Han EK, et al. Downregulation of Akt1 inhibits anchorage-independent cell growth and induces apoptosis in cancer cells. Neoplasia 2001;3:278-86.
14. Barnett SF, Bilodeau MT, Lindsley CW. The Akt/PKB familyof protein kinases: a review of small molecule inhibitors and progress towards target validation. Curr Top Med Chem 2005;5:109-25.
15. Chen YL, Law PY, Loh HH. Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy. Curr Med Chem Anticancer Agents 2005;5:575-89.
16. Luo Y, Shoemaker AR, Liu X, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 2005;4:977-86.
17. Barnett SF, Defeo-Jones D, Fu S, et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 2005;385:399-408.
18. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003;2:1093-103.
19. Meuillet EJ, Mahadevan D, Vankayalapati H, et al. Specific inhibition of the Akt1 pleckstrin homologydomain by D-3-deoxy-phosphatidyl- myoinositol analogues. Mol Cancer Ther 2003;2:389-99.
20. Martelli AM, Tazzari PL, Tabellini G, et al. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia 2003;17:1794-805.
21. Jones PF, Jakubowicz T, Pitossi FJ, Maurer F, Hemmings BA. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci U S A 1991;88:4171-5.
22. Klippel A, Reinhard C, Kavanaugh WM, Apell G, Escobedo MA, Williams LT. Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways. Mol Cell Biol 1996;16:4117-27.
23. Kishimoto A, Nishiyama K, Nakanishi H, et al. Studies on the phosphorylation of myelin basic protein by protein kinase C and adenosine 3′:5′-monophosphate-dependent protein kinase. J Biol Chem 1985;260:12492-9.
24. Toral-Barza L, Zhang WG, Lamison C, Larocque J, Gibbons J, Yu K. Characterization of the cloned full-length and a truncated human target of rapamycin: activity, specificity, and enzyme inhibition as studied by a high capacity assay. Biochem Biophys Res Commun 2005;332:304-10.
25. Zhang X, Zhang S, Yamane H, et al. Kinetic mechanism of AKT/PKB enzyme family. J Biol Chem 2006;281:13949-56.
26. Huang X, Begley M, Morgenstern KA, et al. Crystal structure of an inactive Akt2 kinase domain. Structure 2003;11:21-30.
27. Yang J, Cron P, Good VM, Thompson V, Hemmings BA, Barford D. Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat Struct Biol 2002;9:940-4.
28. Reusch HP, Zimmermann S, Schaefer M, Paul M, Moelling K. Regulation of Raf by Akt controls growth and differentiation in vascular smooth muscle cells. J Biol Chem 2001;276:33630-7.
29. Cuevas BD, Abell AN, Johnson GL. Role of mitogen-activated protein kinase kinase kinases in signal integration. Oncogene 2007;26:3159-71.
30. Ruggero D, Sonenberg N. The Akt of translational control. Oncogene 2005;24:7426-34.
31. Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001;8:249-58.
32. Brunn GJ, Hudson CC, Sekulic A, et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 1997;277:99-101.
33. Lawrence JC, Jr., Abraham RT. PHAS/4E-BPs as regulators of mRNA translation and cell proliferation. Trends Biochem Sci 1997;22:345-9.
34. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. The antiinflammatory natural product parthenolide from the medicinal herb feverfew directly binds to and inhibits IκB kinase. Chem Biol 2001;8:759-66.
35. Murata H, Ihara Y, Nakamura H, Yodoi J, Sumikawa K, Kondo T. Glutaredoxin exerts an antiapoptotic effect by regulating the redox state of Akt. J Biol Chem 2003;278:50226-33.
36. Rabindran SK, Discafani CM, Rosfjord EC, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004;64:3958-65.
37. Holz MK, Ballif BA, Gygi SP, Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 2005;123:569-80.
38. Harris TE, Chi A, Shabanowitz J, Hunt DF, Rhoads RE, Lawrence JC, Jr. mTOR-dependent stimulation of the association of eIF4G and eIF3 by insulin. EMBO J 2006;25:1659-68.
39. Clemens MJ. Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene 2004;23:3180-8.
40. Bjornsti MA, Houghton PJ. Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell 2004;5:519-23.
41. Nomoto K, Okabe T, Suzuki H, Tanaka N. Mechanism of action of lactoquinomycin A with special reference to the radical formation. J Antibiot (Tokyo) 1988;41:1124-9.